• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Jordan Julie

    1/18/24 6:45:23 PM ET
    $NLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NLTX alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Jordan Julie

    (Last) (First) (Middle)
    C/O NEUROGENE INC.
    535 W 24TH STREET, 5TH FLOOR

    (Street)
    NEW YORK NY 10011

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    01/16/2024
    3. Issuer Name and Ticker or Trading Symbol
    Neurogene Inc. [ NGNE ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Medical Officer
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    Exhibit 24 - Power of Attorney
    No securities are beneficially owned.
    /s/ Christine Mikail, as attorney-in-fact for Julie Jordan 01/18/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $NLTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NLTX

    DatePrice TargetRatingAnalyst
    3/2/2022$30.00 → $25.00Overweight
    Piper Sandler
    8/6/2021$30.00Overweight
    Piper Sandler
    More analyst ratings

    $NLTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Woods Robert Keith

      4 - Neurogene Inc. (0001404644) (Issuer)

      1/18/24 7:01:01 PM ET
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Palekar Rohan

      4 - Neurogene Inc. (0001404644) (Issuer)

      1/18/24 6:58:27 PM ET
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Noonberg Sarah B.

      4 - Neurogene Inc. (0001404644) (Issuer)

      1/18/24 6:56:12 PM ET
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NLTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Neoleukin Therapeutics Announces 1-for-4 Reverse Stock Split

      SEATTLE, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" or the "Company" (NASDAQ:NLTX), a biopharmaceutical company that has designed de novo protein therapeutics utilizing sophisticated computational methods, today announced that its Board of Directors ("Board") has approved a reverse stock split of the Company's outstanding shares of common stock at a ratio of 1-for-4. The reverse stock split will become effective at 12:02 a.m., Eastern Time on December 18, 2023. The Company's common stock is expected to begin trading on a post-reverse stock split basis on the Nasdaq Global Market on December 19, 2023, under the new name Neurogene Inc. and under the new symbo

      12/14/23 7:00:00 PM ET
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split

      SEATTLE, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" or the "Company" (NASDAQ:NLTX), a biopharmaceutical company that has designed de novo protein therapeutics utilizing sophisticated computational methods, today announced that its Board of Directors ("Board") has approved a reverse stock split of the Company's outstanding shares of common stock at a ratio of 1-for-5. The reverse stock split will become effective at 12:01 a.m. Eastern time on September 25, 2023. Neoleukin's common stock will begin trading on a post-reverse stock split basis on September 25, 2023, under Neoleukin's existing trading symbol "NLTX" with a new CUSIP number 64049K203. The reverse

      9/22/23 8:00:00 AM ET
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lifshitz Law PLLC Announces Investigations of HCCI, PRDS, NLTX, CCF

      NEW YORK, July 22, 2023 (GLOBE NEWSWIRE) -- Heritage-Crystal Clean, Inc. (NASDAQ:HCCI) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of HCCI to an investment affiliate of J.F. Lehman & Company for $45.50 per share in cash for each share of HCCI common stock owned. If you are a HCCI investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected]. Pardes Biosciences, Inc. (NASDAQ:PRDS) Lifshitz Law PLLC announces an investigation into possible breach of fiducia

      7/22/23 8:07:00 PM ET
      $CCF
      $HCCI
      $NLTX
      $PRDS
      Building Products
      Consumer Discretionary
      Miscellaneous
      Industrials

    $NLTX
    SEC Filings

    See more
    • SEC Form 144 filed by Neoleukin Therapeutics Inc.

      144 - Neurogene Inc. (0001404644) (Subject)

      2/9/24 4:35:58 PM ET
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Neoleukin Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Neurogene Inc. (0001404644) (Filer)

      1/5/24 7:11:07 AM ET
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Neoleukin Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics, Shareholder Director Nominations, Regulation FD Disclosure

      8-K - Neurogene Inc. (0001404644) (Filer)

      12/19/23 7:31:02 AM ET
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NLTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Piper Sandler reiterated coverage on Neoleukin Therapeutics with a new price target

      Piper Sandler reiterated coverage of Neoleukin Therapeutics with a rating of Overweight and set a new price target of $25.00 from $30.00 previously

      3/2/22 8:41:36 AM ET
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler resumed coverage on Neoleukin Therapeutics with a new price target

      Piper Sandler resumed coverage of Neoleukin Therapeutics with a rating of Overweight and set a new price target of $30.00

      8/6/21 7:21:14 AM ET
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NLTX
    Financials

    Live finance-specific insights

    See more
    • Neurogene and Neoleukin Announce Definitive Merger Agreement

      Proposed merger to create Nasdaq-listed biotech company focused on advancing Neurogene's differentiated portfolio of genetic medicines for complex neurological diseases Combined company is expected to have a cash balance of approximately $200 million at close, including approximately $95 million from concurrent private financing by Neurogene's new and existing investors Cash expected to fund combined company into 2H:26 and through multiple catalysts, including preliminary data in 4Q:24 and additional data in 2H:25 from a Phase 1/2 clinical trial in Rett syndrome Companies to host conference call today at 8:30 am ET NEW YORK and SEATTLE, July 18, 2023 (GLOBE NEWSWIRE) -- Neurogene Inc.,

      7/18/23 6:30:00 AM ET
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Neoleukin Therapeutics Announces Second Quarter 2022 Financial Results & Provides Corporate Update

      SEATTLE, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results for the second quarter ended June 30, 2022 and a midyear corporate update. "Our focus at Neoleukin is the advancement of de novo proteins to solve important therapeutic challenges and address unmet medical needs," said Jonathan Drachman, M.D., Chief Executive Officer of Neoleukin. "We are excited to be part of a revolutionary approach to creating therapeutic proteins that are not based on native sequences. Our first programs, including our lead

      8/9/22 4:02:00 PM ET
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Neoleukin Therapeutics to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 9, 2022

      SEATTLE, July 27, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), today announced it will report second quarter 2022 financial results on Tuesday, August 9, 2022 after the close of financial markets and then host a conference call and live audio webcast to discuss these results and provide a corporate update. Details of the event are as follows: Date: Tuesday, August 9, 2022 Time: 1:30 p.m. Pacific / 4:30 p.m. Eastern Toll-free: (800) 715-9871 Conference ID: 4116795 Webcast URL: http://investor.neoleukin.com/events The archived audio webcast will be available on the Investor Relations section of the Neoleukin website approximately two hours after the

      7/27/22 8:00:00 AM ET
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NLTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Neoleukin Therapeutics Provides Strategic Update and Announces Restructuring and Leadership Transition

      SEATTLE, March 08, 2023 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that it has engaged SVB Securities to assist in reviewing strategic alternatives for the Company with the goal of maximizing shareholder value. Such alternatives may include a sale, merger, divestiture of assets, licensing or other strategic transaction. There can be no assurance that the exploration of strategic alternatives will result in any agreements or transactions, or that, if completed, any agreements or transactions will be successful or on attractive te

      3/8/23 5:00:00 PM ET
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Neoleukin Therapeutics Announces First Quarter 2022 Financial Results and Corporate Update

      SEATTLE, May 09, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results for the quarter ending March 31, 2022 and provided a corporate update. "During the first quarter of 2022 our dedicated team at Neoleukin has been focused on execution of our NL-201 Phase 1 clinical trial, evaluating multiple schedules during dose escalation in patients with relapsed and refractory solid tumors," said Jonathan Drachman, M.D., Chief Executive Officer of Neoleukin. "We anticipate reporting interim data from this trial during the sec

      5/9/22 4:05:00 PM ET
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Neoleukin Therapeutics Announces Appointment of Donna Cochener as General Counsel

      SEATTLE, March 15, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the appointment of Donna M. Cochener as General Counsel, Senior Vice President Legal. Ms. Cochener joins Neoleukin after serving as Senior Vice President, Deputy General Counsel at HomeStreet, Inc., the parent company of HomeStreet Bank. In that role, she was primarily responsible for securities reporting and compliance and corporate governance as well as serving as lead attorney on a range of transactions, including mergers and acquisitions and debt and equit

      3/15/22 8:00:00 AM ET
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NLTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Neoleukin Therapeutics Inc.

      SC 13G - Neurogene Inc. (0001404644) (Subject)

      2/14/24 6:05:00 PM ET
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Neoleukin Therapeutics Inc. (Amendment)

      SC 13G/A - Neurogene Inc. (0001404644) (Subject)

      2/14/24 4:37:55 PM ET
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Neoleukin Therapeutics Inc. (Amendment)

      SC 13G/A - Neurogene Inc. (0001404644) (Subject)

      2/14/24 4:26:22 PM ET
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care